Intra-Cellular Therapies Presents the ITI-007 Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research

NEW YORK, March 31, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, presented data regarding the ITI-007 development program and described the rationale supporting the strategy for the advancement of ITI-007 in multiple clinical indications at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs.

In a poster the Company described the rationale for dose selection in the ongoing Phase 3 clinical trial in schizophrenia. Preclinical data predicted antipsychotic efficacy at human equivalent doses as low as 20 – 40 mg of ITI-007. Positron emission tomography (PET) data in healthy volunteers demonstrated striatal D2 receptor occupancy of ~20% and ~40% at doses of 20 mg and 40 mg, respectively. Striatal D2 receptor occupancy at 60 mg was projected to be approximately 50%. In a Phase 2 clinical trial in patients with schizophrenia, ITI-007 at a dose of 60 mg demonstrated a statistically significant and clinically meaningful improvement in psychosis with a favorable metabolic, cardiovascular and motor adverse event profile.

Based on the preclinical and clinical results described above the Company selected doses of 60 mg and 40 mg of ITI-007 for the ongoing Phase 3 clinical trial in schizophrenia. This study, ITI-007-301, is a randomized, double-blind, placebo-controlled, inpatient clinical trial in patients with an acutely exacerbated episode of schizophrenia. In this trial, over 400 patients are expected to be randomized to receive one of three treatments: 60 mg ITI-007, 40 mg ITI-007 or placebo in a 1:1:1 ratio. The Company anticipates topline results from this trial will be available in the second half of 2015.

In an oral presentation the Company summarized the clinical progress of ITI-007 to date and emphasized its rationale supporting the development of ITI-007 for other indications. ITI-007 has a unique pharmacological profile acting as a serotonergic, dopaminergic, and glutamatergic modulator. In addition, ITI-007 has a dose-dependent pharmacology. At low doses, ITI-007 acts mainly as a potent 5-HT2A receptor antagonist, with modest interaction with other drug targets. As the dose is increased, additional pharmacological interactions play a greater role, i.e., dopamine and glutamate receptor modulation and inhibition of SERT are gradually increased. The Company emphasized the pharmacological, pharmacodynamic and safety profile of ITI-007, which supports its development in other indications beyond schizophrenia, including bipolar disorder and major depressive disorder as well as behavioral disturbances in patients with dementia.

ITI-007's unique pharmacology, including its activity at the serotonergic, dopaminergic, and glutamatergic systems, is associated with reduction in symptoms associated with depression. In the Phase 2 schizophrenia trial, a 60 mg dose of ITI-007 resulted in marked antidepressant effects in patients with schizophrenia and co-morbid depression. The drug's unique pharmacological activity also supports potential efficacy for the treatment of bipolar disorder and major depressive disorder.

In addition, low doses of ITI-007 have the potential to reduce behavioral disturbances in patients with dementia (including Alzheimer's disease) such as a reduction in agitation and irritability, improvements in mood and emotional stress as well as improvement in sleep. Low doses of ITI-007, up to and including 30 mg were demonstrated to be safe and well tolerated in a clinical trial of healthy geriatric subjects and elderly patients with dementia. The Company believes that these characteristics, when coupled with the drug's favorable safety and tolerability profile and the pro-social profile of ITI-007's clinical effects, result in a differentiated profile across multiple indications.

"We are undertaking a robust clinical development program for ITI-007. The key aspects of our ITI-007 program have been designed based on our understanding of the unique pharmacology of ITI-007, the strong existing clinical evidence and the supporting preclinical data. As a result, ITI-007 is being developed as a differentiated treatment in several CNS indications in which important medical needs exist," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical trials for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our clinical and nonclinical development plans, including our expectations concerning the timing of trials and studies and the availability of data; our beliefs about the potential uses and benefits of ITI-007; and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials, other studies for ITI-007, and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC), as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the SEC. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 212-923-3344 Burns McClellan, Inc. Lisa Burns/Nancy Yu (Investors) Justin Jackson (Media) 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 156

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

NewRiver REIT Announces Scrip Dividend Reference Price

Updated Category News Views 335

NewRiver REIT's Scrip Dividend Reference Price Announcement NewRiver REIT plc has made a significant announcement regarding the reference price for its scrip dividend option, which is tied to its interim dividend. This dividend pertains to the six-month period ending on September 30, 2024. Understanding the Scrip Dividend Option The reference price has been set at 73.41...

Continue Reading
Upcoming Shareholders' Meeting Announcement for Siguldas CMAS

Updated Category News Views 200

Important Shareholders' Meeting Information The Management Board of Joint Stock Company ‘Siguldas ciltslietu un m?ksl?g?s aps?klošanas stacija’ is excited to announce an important shareholders' meeting for the company. This meeting is a key opportunity for all shareholders to engage in discussions concerning the company's future. Meeting Details Scheduled for April...

Continue Reading
Empowering Women in Finance: Insights from Cboe Leaders

Updated Category News Views 168

Empowering Women in Finance In a recent dialogue, Cathy Clay, Executive Vice President and Global Head of Derivatives at Cboe, along with Meghan Dugan, Senior Vice President overseeing U.S. Options, and Alexandra Szakats, Vice President and Head of The Options Institute, shared their journeys and advice regarding their roles as leaders in the options industry. These women...

Continue Reading
Bird Dog Whiskey Debuts Premium Kentucky Straight Bourbon

Updated Category News Views 220

Bird Dog Whiskey Unveils Select Reserve Kentucky Straight Bourbon Bird Dog Whiskey has exciting news for bourbon enthusiasts. The brand has launched a highly anticipated addition to its lineup: the Select Reserve Kentucky Straight Bourbon Whiskey. This new offering is set to capture the hearts of loyal fans. A Smooth and Rich Bourbon Experience At 86 proof, Bird Dog...

Continue Reading
Vera Therapeutics Announced Key Stock Option Grants for New Hires

Updated Category News Views 160

Introduction to Vera Therapeutics' Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has proudly announced a significant step in its commitment to fostering talent by granting inducement awards to new employees. On a recent date, the Compensation Committee approved these awards, which included stock options and restricted stock units (RSUs) to reward and attract...

Continue Reading